Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822832 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03822832 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 51 participants.
The verdict
NCT03822832, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
Interventions
- DRUG Placebo
- DRUG BI 655130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2020-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822832
The ClinicalTrials.gov registry entry for NCT03822832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03822832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03822832 about?
NCT03822832 is a clinical study titled "A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated". The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
What is the current status of trial NCT03822832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2019-02-12. Estimated completion is 2020-07-22.
What interventions are being tested in trial NCT03822832?
The interventions under investigation include: Placebo (DRUG), BI 655130 (DRUG).
Who is sponsoring clinical trial NCT03822832?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.